Literature DB >> 15516537

Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis.

Ross K Morgan1, Stephen McNally, Michael Alexander, Ronan Conroy, Orla Hardiman, Richard W Costello.   

Abstract

Respiratory muscle weakness is the usual cause of death in amyotrophic lateral sclerosis. The prognostic value of the forced vital capacity (FVC), mouth-inspiratory force, and sniff nasal-inspiratory force were established in a group of 98 patients with amyotrophic lateral sclerosis who were followed trimonthly for 3 years. Sniff nasal-inspiratory force correlated with the transdiaphragmatic pressure (r = 0.9, p < 0.01). Sniff nasal-inspiratory force was most likely to be recorded at the last visit (96% of cases), compared with either the FVC or mouth-inspiratory force (86% and 81%, respectively, p < 0.01). A sniff nasal-inspiratory force less than 40 cm H(2)O was significantly related with nocturnal hypoxemia. When sniff nasal-inspiratory force was less than 40 cm H(2)O, the hazard ratio for death was 9.1 (p = 0.001), and the median survival was 6 +/- 0.3 months. The sensitivity of FVC < 50% for predicting 6-month mortality was 58% with a specificity of 96%, whereas sniff nasal-inspiratory force less than 40 H(2)O had a sensitivity of 97% and a specificity of 79% for death within 6 months. Thus the sniff nasal-inspiratory force test is a good measure of respiratory muscle strength in amyotrophic lateral sclerosis, it can be performed by patients with advanced disease, and it gives prognostic information.

Entities:  

Mesh:

Year:  2004        PMID: 15516537     DOI: 10.1164/rccm.200403-314OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

1.  Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline.

Authors:  Douglas A McKim; Jeremy Road; Monica Avendano; Steve Abdool; Fabien Cote; Nigel Duguid; Janet Fraser; Fracois Maltais; Debra L Morrison; Colleen O'Connell; Basil J Petrof; Karen Rimmer; Robert Skomro
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

2.  Management of symptoms in amyotrophic lateral sclerosis.

Authors:  Lisa S Thibodeaux; Amparo Gutierrez
Journal:  Curr Treat Options Neurol       Date:  2008-03       Impact factor: 3.598

Review 3.  Diagnostic investigation and multidisciplinary management in motor neuron disease.

Authors:  J A Rocha; C Reis; F Simões; J Fonseca; J Mendes Ribeiro
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

Review 4.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

5.  ARTP statement on pulmonary function testing 2020.

Authors:  Karl Peter Sylvester; Nigel Clayton; Ian Cliff; Michael Hepple; Adrian Kendrick; Jane Kirkby; Martin Miller; Alan Moore; Gerrard Francis Rafferty; Liam O'Reilly; Joanna Shakespeare; Laurie Smith; Trefor Watts; Martyn Bucknall; Keith Butterfield
Journal:  BMJ Open Respir Res       Date:  2020-07

Review 6.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

7.  Respiratory muscle training in late-onset Pompe disease: Results of a sham-controlled clinical trial.

Authors:  Harrison N Jones; Maragatha Kuchibhatla; Kelly D Crisp; Lisa D Hobson-Webb; Laura Case; Milisa T Batten; Jill A Marcus; Richard M Kravitz; Priya S Kishnani
Journal:  Neuromuscul Disord       Date:  2020-09-28       Impact factor: 4.296

Review 8.  Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management.

Authors:  Paul H Gordon
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

9.  Respiratory and nutritional support in amyotrophic lateral sclerosis.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2014-02       Impact factor: 3.598

10.  A population based study of respiratory function in motor neuron disease patients living in Tayside and North East Fife, Scotland.

Authors:  Shuna Colville; Robert J Swingler; Ian S Grant; Fiona L R Williams
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.